A Phase 2 interventional study of Investigational Drug, MW-III and Silvadene® Cream 1% [Silver Sulfadiazine] in Burns, sponsored by Skingenix, Inc.. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Skingenix, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 336 studies in Burns with a site in United States — 40 open to participants now, 52 under way, 5 of them phase 3. Burns · United States.
Among the 336 studies in Burns with a site in United States, this one is the 59th largest by planned enrollment of the 272 interventional ones that give a count, is one of 13 that started in 2022, is one of 32 in phase 2, reaches primary completion later than 18 of the 51 other live ones, and was the 116th registered.
906 studies on the registry are indexed under Burns; 165 are open to participants now.
Browse Burns studies →40 of the 336 studies in Burns with a site in United States are open now. Recruiting first, the newest first:
Jason Sperry · Sites in United States
Ages 18–75
Henry M. Jackson Foundation for the Advancement of Military Medicine · Sites in United States
Ages 18–80
Henry M. Jackson Foundation for the Advancement of Military Medicine · Sites in United States
Ages 18–80
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 85 Burns studies recruiting now, 38 (45%) set no upper age limit and 38 (45%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
336 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 56 · Phase 3 30 · Phase 4 25
First in 1992; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 40 across 664 interventional studies indexed under Burns.
Median enrollment 26 across the 272 interventional studies, 59 across the 61 observational. Of the 225 that completed or were terminated, 74 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 336 have an industry lead sponsor. The 10 most frequent:
Skingenix, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Skingenix, Inc. has 1 study filed under Burns — fewer than ten, so there is no comparison to draw.
10 of the studies in Burns with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05223998The Metis FoundationManual Implantation of Full-Thickness Skin Microcolumns | 2026-12 |
| NCT07317271Johns Hopkins UniversityVR-PMR for Post-Burn Symptoms | 2026-12 |
| NCT05462860The Metis FoundationSuprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds | 2026-12-09 |
| NCT01297400Skingenix, Inc.Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns | 2026-12-31 |
| NCT07221903University of WashingtonThe Lateral, Anterior, Medial (LAM) Femoral Cutaneous Block: A Case Series Harborview Medical Center, Seattle, WA | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 336 studies in Burns with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
This phase 2 pilot study will assess the safety and efficacy of topical MW-III on thermal burns.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any burn that at screening is:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational Drug, MW-III
Drug: Investigational Drug, MW-III
Silvadene® Cream 1% \[Silver Sulfadiazine\]
Drug: Silvadene® Cream 1% [Silver Sulfadiazine]
Topical application, twice a day
Topical application, twice a day
Time to healing (≥95% re-epithelialization) of the partial thickness target burn.
Time to healing (≥95% re-epithelialization) of the partial thickness target burn.
Time frame: 28 days Treatment Period
Proportion of subjects with partial thickness burns that are healed at each scheduled study assessment.
Proportion of subjects with partial thickness burns that are healed at each scheduled study assessment.
Time frame: 28 days Treatment Period
Proportion of subjects with partial thickness burns determined by PI to require skin grafting of burn wound by Day 28.
Proportion of subjects with partial thickness burns determined by PI to require skin grafting of burn wound by Day 28.
Time frame: 28 days Treatment Period
Scar scores (POSAS) of the partial thickness target burn and all other partial thickness burns at Day 28.
Scar scores (POSAS) of the partial thickness target burn and all other partial thickness burns at Day 28.
Time frame: 28 days Treatment Period
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.
Of 17 phase 2 interventional studies under Burns, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 61. This study's planned 57 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Drugs, Investigational
Skingenix, Inc.